Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $96.72M
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: -71.01%
• EPS Growth: -14.04%
• Country: US
• Employees: 158
• Sector: Healthcare
• Sector Strength: 76
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 93,004,600
• 10 Day Avg. Volume: 943,124
• 30 Day Avg. Volume: 1,003,281
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 9.68
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Caribou Biosciences' overall score reflects significant financial difficulties, including negative income and cash flow issues. The technical outlook is bearish, while the valuation is unattractive due to a negative P/E ratio. However, recent corporate events, such as advancements in CAR-T therapy trials and new leadership, provide some optimism for future growth potential.

Positive Factors

Clinical Trials

The CaMMouflage Ph1 study of CB-011 in r/r multiple myeloma is escalating to DL4 after clearing DL3 with no dose-limiting toxicities and signs of efficacy.

Cost Management

R&D and SG&A expenses were below consensus estimates, indicating effective cost management.

Financial Stability

Caribou ended 2024 with $249.4M in cash, cash equivalents, and marketable securities, which is slated to provide a runway into 2H26.

Negative Factors

Clinical Delays

Planned pivotal trial for CB-010 is delayed by at least six months due to a focus on human leukocyte antigen matching.

Clinical Risks

Risks include negative clinical results with the company's lead assets and delays in advancing these candidates into registrational programs.

Regulatory Approval

The probability of approval for CB-010 has been lowered to 20% from the prior 30% due to the decline in efficacy.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

How the Company Makes Money

Caribou Biosciences generates revenue through a combination of licensing agreements, partnerships, and development collaborations. The company licenses its proprietary CRISPR-Cas9 technology to other biotech firms and research institutions, which allows them to generate upfront fees, milestone payments, and royalties based on the success of the licensed products. Additionally, Caribou engages in strategic partnerships and collaborations with pharmaceutical companies to co-develop novel therapies, sharing both the costs and potential profits of successful treatments. These collaborations often involve joint research efforts and clinical development programs, enhancing Caribou's ability to bring its therapies to market. Furthermore, any proprietary products developed by Caribou and successfully commercialized can also contribute to direct sales revenue.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences faces significant financial challenges, with no revenue and negative profits. While the balance sheet shows a low debt-to-equity ratio, profitability remains elusive, and cash flow deficits persist, indicating financial instability.

Income Statement

Caribou Biosciences has shown no revenue for the latest year, and its net income has been consistently negative, indicating ongoing financial challenges. The revenue growth rate has been volatile, with significant fluctuations year over year. Margins, such as EBIT and EBITDA, are negative, reflecting persistent operational inefficiencies.

Balance Sheet

The company has a strong equity base compared to its debt, resulting in a low debt-to-equity ratio. However, the negative return on equity indicates that the company is not generating profit from its equity. The equity ratio has been relatively stable, suggesting a solid capital structure despite ongoing losses.

Cash Flow

Caribou Biosciences has negative operating and free cash flows, highlighting cash management issues. The cash flow to net income ratios are not favorable, reflecting cash flow challenges. The company has been reliant on financing activities to cover cash flow deficits.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.99M	34.48M	13.85M	9.60M	12.36M
	Gross Profit
9.99M	-77.60M	10.21M	8.61M	-22.06M
	EBIT
-166.62M	-116.06M	-106.40M	-66.98M	-36.12M
	EBITDA
-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
	Net Income Common Stockholders
-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
209.54M	328.83M	317.04M	413.51M	15.95M
	Total Assets
313.31M	432.21M	373.76M	442.36M	36.05M
	Total Debt
26.49M	27.11M	27.75M	259.00K	1.58M
	Net Debt
10.19M	-24.05M	-30.59M	-240.16M	-14.38M
	Total Liabilities
60.36M	63.81M	72.89M	54.53M	59.48M
	Stockholders Equity
252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow		Free Cash Flow
-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
	Operating Cash Flow
-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
	Investing Cash Flow
86.61M	-68.18M	-93.25M	-176.40M	6.36M
	Financing Cash Flow
16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.09, below the 50-day MA of 1.30, and below the 200-day MA of 1.83, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 39.29 is Neutral, neither overbought nor oversold. The STOCH value of 24.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BEAM	50 Neutral	$2.33B	―	-43.94%	―	-83.18%	-144.95%
Sector *	49 Neutral	$6.95B	0.67	-53.43%	2.47%	22.78%	1.44%
CRSP	46 Neutral	$3.54B	―	-19.20%	―	-89.95%	-123.71%
SGMO	41 Neutral	$194.73M	―	-187.83%	―	-67.20%	64.66%
EDIT	39 Underperform	$108.70M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$931.66M	―	-54.00%	―	59.55%	3.09%
CRBU	38 Underperform	$96.72M	―	-47.99%	―	-71.01%	-14.04%

Caribou Biosciences Corporate Events

Caribou Biosciences Advances CAR-T Therapy Trials

Caribou Biosciences announced the initiation of the GALLOP Phase 1 clinical trial for CB-010 in lupus patients and provided significant updates on its CAR-T cell therapy programs for hematologic malignancies. The company plans to present data from several Phase 1 trials and potentially begin a pivotal Phase 3 trial in 2025, contingent on positive results. These developments are expected to enhance Caribou’s position in the allogeneic CAR-T cell therapy market, offering broader patient access and quicker treatment availability.

Caribou Biosciences Appoints New CFO Amid Clinical Advancements

Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025. Ryali, with 20 years of experience in the biopharmaceutical industry, will oversee strategic leadership in corporate finance, investor relations, and corporate communications. His appointment is timed with the company’s advancement of four clinical-stage programs and the disclosure of multiple datasets in 2025. Ryali’s extensive background in finance roles at several biopharmaceutical companies is expected to support Caribou’s ongoing efforts to deliver off-the-shelf CAR-T cell therapies to patients.